OBJECTIVES: Economic burden of multiple myeloma patients in Egypt who are transplant eligible, has not been yet established. The aim of the present study was to evaluate the economic burden of refractory/ relapsed multiple myeloma (RRMM) who are transplant eligible from patient’s perspective over 1 year.

METHODS: An economic model calculating the total costs from patient perspective was conducted to measure the annual costs of RR MM patients receiving daratumumab, bortezomib and dexamethasone regimen for 7.4 months followed by autologous hematopoietic cell transplantation (HCT). This analysis was based on the Egyptian clinical practice and validated from published sources. The length of a cycle was 21 days. The clinical parameters were derived from randomized trial previously published. Direct medical costs were obtained from the public costs. All costs were reported in Egyptian pounds of the financial year 2021. A sensitivity analysis was conducted.

RESULTS: The total cost per patient receiving bortezomib, dexamethasone and daratumumab regimen followed by autologous hematopoietic cell transplantation (HCT) was estimated to be 1,933,580.87 EGP. One way sensitivity analysis revealed that the variable parameters does not impact the final results.

CONCLUSIONS: The present study concludes that, from patient’s perspective, the economic burden of RRMM patient who are transplant eligible was burdensome and costly. This study helps to inform decisions about the allocation of health care system resources and to achieve better health in the Egyptian population.